Epidiolex

Two big news items dominated the cannabis industry this week: the re-scheduling of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s cannabis-derived drug, Epidiolex, from the Schedule I category to the Schedule V category; and High Times’ acquisition of Dope Magazine for $11.2 million in...

Amid the controversies surrounding the legalization of cannabis and associated products, gradual advancements have been made this year. As of Sept. 27, a specific type of cannabidiol, or CBD oil will be federally legal in the United States. What Happened The U.S. Drug Enforcement Administration...

Even before word of the DEA's landmark rescheduling of cannabidiol (CBD) for GW Pharmaceuticals (NASDAQ: GWPH) FDA-approved Epidiolex, the cannabis market has had a hot summer. Medical cannabis is now legal in 31 states and the District of Columbia, with adult-use markets open in 9 of them plus...

By Sunday night, the U.S. Drug Enforcement Administration is expected to reclassify GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s Epidiolex to allow medicinal use. This could open the therapy to a new and promising market. The Analyst  Morgan Stanley analyst David Lebowitz ...

After a huge year in 2017, GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock has traded mostly sideways so far in 2018. But one analysts believes GW will soon return to its winning ways. The Analyst Stifel analyst Paul Matteis initiated coverage of GW Pharma with a Buy rating and $181 price target....

It was another extremely busy week for the cannabis industry. Voters in Oklahoma chose to legalize medical marijuana, becoming the 30th U.S. state to do so; GW Pharmaceuticals (NASDAQ: GWPH) got the first-ever FDA approval for a cannabis-based drug; Ice Cube’s Big3 basketball league...

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)'s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch.  The Analyst Bank of America'...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) made history Monday when the company’s Epidiolex became the first cannabis-based drug ever approved by the FDA. New Cannabis Ventures and 420 Investor founder Alan Brochstein joined the PreMarket Prep trading show on Tuesday to discuss the...

As expected, the U.S. Food and Drug Administration on Monday approved GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH)'s Epidiolex for the treatment of epilepsy, specifically for people who suffer with Lennox-Gastaut and Dravet syndromes. Why It’s Important The drug is derived from the...

The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved by the agency previously, either as a single ingredient drug, or as part of a...